- Home
- OC vs RPRX Comparison
OC vs RPRX Comparison
Compare OC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OC
- RPRX
- Stock Information
- Founded
- OC 1938
- RPRX 1996
- Country
- OC United States
- RPRX United States
- Employees
- OC N/A
- RPRX N/A
- Industry
- OC Industrial Machinery/Components
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- OC Industrials
- RPRX Health Care
- Exchange
- OC Nasdaq
- RPRX Nasdaq
- Market Cap
- OC 13.8B
- RPRX 11.8B
- IPO Year
- OC N/A
- RPRX 2020
- Fundamental
- Price
- OC $194.04
- RPRX $25.70
- Analyst Decision
- OC Buy
- RPRX Strong Buy
- Analyst Count
- OC 14
- RPRX 6
- Target Price
- OC $193.67
- RPRX $41.67
- AVG Volume (30 Days)
- OC 750.1K
- RPRX 2.5M
- Earning Date
- OC 11-06-2024
- RPRX 11-06-2024
- Dividend Yield
- OC 1.24%
- RPRX 3.27%
- EPS Growth
- OC N/A
- RPRX 518.56
- EPS
- OC 11.72
- RPRX 2.55
- Revenue
- OC $10,439,000,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- OC $16.75
- RPRX $12.38
- Revenue Next Year
- OC $9.24
- RPRX $11.26
- P/E Ratio
- OC $16.56
- RPRX $10.06
- Revenue Growth
- OC 8.09
- RPRX N/A
- 52 Week Low
- OC $129.25
- RPRX $25.10
- 52 Week High
- OC $199.54
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- OC 62.97
- RPRX 30.45
- Support Level
- OC $189.86
- RPRX $26.08
- Resistance Level
- OC $199.54
- RPRX $28.36
- Average True Range (ATR)
- OC 5.71
- RPRX 0.60
- MACD
- OC 0.92
- RPRX -0.13
- Stochastic Oscillator
- OC 77.97
- RPRX 18.40
About OC Owens Corning Inc New
Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with three reportable segments: Composites, Insulation, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.